# OnCo record efbemalenograstim-alfa (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/efbemalenograstim-alfa/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "efbemalenograstim-alfa" ;
  schema:name "Efbemalenograstim alfa"@en ;
  schema:alternateName "F-627"@en, "Ryzneuta" ;
  schema:description "Efbemalenograstim alfa (Ryzneuta) is a once-per-cycle white cell booster, an alternative to pegfilgrastim, that reduces the risk of febrile infections after chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/efbemalenograstim-alfa/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Efbemalenograstim_alfa> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/ryzneuta>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=efbemalenograstim> ;
  onco:status "approved" ;
  onco:tag "ema-list", "supportive" ;
  onco:modality "Long-acting recombinant G-CSF dimer (Fc fusion)" ;
  onco:approval "US 2023: Decrease in febrile neutropenia in adults with non-myeloid malignancies on myelosuppressive chemotherapy", "EU 2024: Reduction in duration of neutropenia and febrile neutropenia after cytotoxic chemotherapy in adults (excluding CML and MDS)" ;
  onco:related <https://onco.cc/drugs/pegfilgrastim/>, <https://onco.cc/drugs/filgrastim/> ;
  onco:technologies <https://onco.cc/technologies/g-csf-growth-factors/> ;
  onco:companies <https://onco.cc/companies/evive-biotech/> ;
  onco:trials <https://onco.cc/trials/nct03252431/>, <https://onco.cc/trials/nct04174599/>, <https://onco.cc/trials/nct02872103/> .